Cart
sales@molnova.com
Home - Products - Endocrinology/Hormones - Estrogen Receptor/ERR - Palazestrant

Palazestrant

Palazestrant

Catalog No. M36480

Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.

Size Price / USD Stock Quantity
2MG 445 Get Quote
5MG 686 Get Quote
10MG 938 Get Quote
25MG 1398 Get Quote
50MG 1822 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Palazestrant
  • Brief Description
  • Description
  • Storage
  • Note
    Research use only, not for human use.
  • Reference
    1. Harmon CL, et al. Methods of treating estrogen receptor-associated diseases such as ER+/HER2+ cancer using an estrogen receptor antagonist: World Intellectual Property Organization, WO2023283329. 2023-01-12.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • ARV-471

    ARV-471 is a best-in-class, orally active Cereblon -based estrogen receptor ( ER ) PROTAC degrader. ARV-471 is developed for the research of breast cancer.

  • Palazestrant

    Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.

  • 4-Hydroxytamoxifen

    A selective estrogen receptor modulator (SERM) and the major active metabolite of tamoxifen.

Sign In Join Free